Rhodes Pharmaceuticals Recalls Aptensio XR Capsules Due to Dissolution Failure
Rhodes Pharmaceuticals is recalling Aptensio XR capsules because they failed to meet dissolution specifications. The affected lot was distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates a low risk of adverse health consequences. The defect is a failure to meet dissolution specifications, which is a quality control issue rather than a direct safety hazard like contamination or mislabeling.
Plain-English summary
Rhodes Pharmaceuticals, L.P. is recalling Aptensio XR (methylphenidate HCl extended-release) capsules, 15 mg, 90-count bottles. The recall involves 2,454 bottles from Lot # AG8679B with an expiration date of 01/2020. The product was distributed nationwide within the United States.
The recall was initiated because the product failed to meet dissolution specifications, specifically showing low dissolution outside of the required standards. This defect means the medication may not release the active ingredient as intended.
Consumers who have this specific lot of Aptensio XR should stop using it and contact their healthcare provider or pharmacist for guidance. The product is marketed by Rhodes Pharmaceuticals, L.P., and manufactured by Patheon Manufacturing Services LLC.
The recalled product
- Product
- Aptensio XR (methylphenidate HCl extended-release) capsules 15 mg Rx Only 90-count bottle. Marketed by: Rhodes Pharmaceuticals L.P., Coventry, RI 02816. Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834. NDC 42858-402-45
- Manufacturer
- Rhodes Pharmaceuticals, L.P.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 2,454
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot# AG8679B Exp. 01/2020
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Rhodes Pharmaceuticals, L.P.
See all →- HighOxycodone Hydrochloride Tablets Recalled for Foreign Tablet Contamination
FDA (Drugs) · 2021-09-22
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17